Form 8-K - Current report:
SEC Accession No. 0001213900-25-059303
Filing Date
2025-06-30
Accepted
2025-06-30 09:25:36
Documents
14
Period of Report
2025-06-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0247469-8k_unicycive.htm   iXBRL 8-K 35088
2 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED JUNE 30, 2025 ea024746901ex99-1_unicycive.htm EX-99.1 15868
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5052
  Complete submission text file 0001213900-25-059303.txt   231755

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE uncy-20250630.xsd EX-101.SCH 3017
5 XBRL LABEL FILE uncy-20250630_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE uncy-20250630_pre.xml EX-101.PRE 22360
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0247469-8k_unicycive_htm.xml XML 3775
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

EIN.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 251088969
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)